Podcasts

Episode 3 | 2020 Wrap: Remarkable Progress In Diagnosing & Treating Lung Cancer

Prof Nick Pavlakis and Prof Emily Stone join discuss the remarkable advances in screening, diagnosing and treating lung cancer that occurred during 2020.

2020 Wrap: Remarkable Progress In Diagnosing & Treating Lung Cancer

Episode Summary

Prof Nick Pavlakis and Prof Emily Stone discuss the remarkable advances in screening, diagnosing, and treating lung cancer. This episode delves into the public health measures to ensure the survival increase we are seeing for patients with lung cancer continues to accelerate into this decade.

 

Sponsored with a Takeda Educational Grant.

Show Hosts

This episode’s host are:

  • Prof Nick Pavlakis, Chair, TOGA; Senior Staff Specialist, Department of Medical Oncology, Royal North Shore Hospital
  • Prof Emily Stone, Deputy Chair, TOGA; Respiratory Physician, Senior Staff Specialist and Head of Thoracic Medicine, Department of Thoracic Medicine and Lung Transplantation, St Vincent’s Hospital Sydney; conjoint Senior Lecturer, University of New South Wales; Chair, St Vincent’s Hospital Lung Cancer Multidisciplinary team

Play Episode 3 | 2020 Wrap: Remarkable Progress In Diagnosing & Treating Lung Cancer

More Podcasts

In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and
In this introductory episode, A/Prof Mel Moore, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.'
Dr Rebecca Tay is joined by Professor Ben Solomon and A/Prof Michael Ng to discuss clinical and genetic factors affecting treatment choice for ALK-Positive NSCLC
Dr Deme Karikios is joined by Dr Lauren Brown and Dr Stephen Barnett to discuss IO in early-stage NSCLC in the Australian context.
A/Prof Rachel Wong is joined by Dr Patrick Hosking, Dr Mal Itchins, and Dr Sagun Parakh discuss the diagnostic markers when identifying LC-NEC.
We dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining